Grants Search Results
Need help? Call us at (888) 899-2253
Interested in applying for a St. Baldrick's Foundation grant? Learn more about the grant application process.
Showing 101-120 of 284 results
Kimberly Riehle M.D.
Funded: 07-01-2018
through 12-30-2019
Funding Type: Research Grant
Institution Location:
Seattle, WA
Institution: University of Washington
affiliated with Fred Hutchinson Cancer Research Center, Seattle Children's Hospital
The goal of Dr. Riehle's research is to find a cure for a rare form of liver cancer that occurs in children and young adults, called fibrolamellar hepatocellular carcinoma (FL-HCC). Unfortunately, surgery is currently the only effective treatment option for these patients, and once the disease has spread outside of the liver there is no chance for cure. Dr. Riehle's laboratory has spent the last few years trying to understand what changes within the liver cause healthy kids to get this cancer, and has developed a couple of new models of FL-HCC that can be used for drug screening. In this project she is using these models to test new treatment options and to try to understand how this cancer develops.
Jean-Francois Rual Ph.D.
Funded: 07-01-2018
through 06-30-2020
Funding Type: Research Grant
Institution Location:
Ann Arbor, MI
Institution: University of Michigan
affiliated with C.S. Mott Children’s Hospital
Millions of cells are formed every day in the developing brain of children. Medulloblastoma, a pediatric tumor, occurs when the proliferation of cells in the cerebellum (a lower part of the brain) becomes uncontrolled. The Notch pathway is a key mechanism that governs cell proliferation in many biological contexts. Aberrant up-regulation of Notch signals is associated with medulloblastoma. Re-gaining control of Notch could help cure medulloblastoma patients. As the recipient of the Hope for Daisy Research Fund for Pediatric Brain Tumors St. Baldrick's Research Grant, Dr. Rual's goal is to better understand the molecular mechanisms that control Notch signals in brain cells and, thus, to define novel therapeutic targets for the benefit of medulloblastoma patients. He recently identified the L3MBTL3 gene as a new modulator of Notch signals. Importantly, previous studies have shown that the L3MBTL3 genes is deleted in medulloblastoma patients. Dr. Rual hypothesizes that the L3MBTL3 deletions observed in medulloblastoma patients result in the aberrant regulation of Notch signals, thus supporting tumorigenesis. Dr. Rual's team will test this hypothesis by studying the extent to which inhibiting L3MBTL3 modulate medulloblastoma tumor progression in models of medulloblastoma. This study could offer critical mechanistic insights on the role of the L3MBTL3 in medulloblastoma that could be harnessed in the future for the therapeutic benefit of medulloblastoma patients. This grant is funded by and named for the Hope for Daisy Research Fund for Pediatric Brain Tumors, a St. Baldrick's Hero Fund. Diagnosed with medulloblastoma at the age of six, Daisy Walsh met the challenge head on with joy, strength and laughter. Days before her eighth birthday, the tumor recurred and despite her brave battle, Daisy passed away in February 2020. This fund honors her courageous spirit by helping to raise awareness and funds for research to increase survival rates and hope for all children battling brain cancer.
Kristopher Sarosiek Ph.D.
Funded: 07-01-2018
through 06-30-2019
Funding Type: Research Grant
Institution Location:
Boston, MA
Institution: Harvard T.H. Chan School of Public Health
Although patients with certain types of brain tumors are frequently cured by well-established treatments, patients that experience tumor relapse have limited treatment options and frequently succumb to their disease. In addition, the side effects resulting from radiation therapy result in lifelong and devastating cognitive impairment. As the recipient of the Making Headway Foundation St. Baldrick's Research Grant, Dr. Sarosiek recently found that decreasing the expression of BET proteins with a targeted drug can enhance the radiation sensitivity of brain tumors while reducing radiation sensitivity in healthy brain cells, thus supporting increased cure rates and decreased treatment-associated toxicities. In this project, Dr. Sarosiek is directly testing the sensitivity of medulloblastomas to BET inhibitors, alone and in combination with radiation therapy and chemotherapy; and determining the extent to which BET inhibitors can protect critical brain cells from radiation treatment. Importantly, BET inhibitors are currently being evaluated in clinical trials for other cancers and are thus readily available for clinical deployment for treatment of pediatric patients with medulloblastomas. Knowledge gained in these studies will serve as a foundation for the testing of BET inhibitors in clinical trials in children diagnosed with medulloblastomas and potentially other CNS tumors to dramatically improve treatment outcomes. This grant is named for the Making Headway Foundation whose mission for the past 20 years has been to provide care and comfort for children with brain and spinal cord tumors through a continuum of services and programs while also funding medical research for cures.
Marina Sokolsky-Papkov PhD
Funded: 07-01-2018
through 06-30-2019
Funding Type: Research Grant
Institution Location:
Chapel Hill, NC
Institution: University of North Carolina at Chapel Hill
affiliated with UNC Children's Hospital
Medulloblastoma is the most common malignant brain tumor of children. New approaches to treatment are needed, because current treatment can cause brain injury and fails too many patients. Some medulloblastomas are driven by excessive activity of a signaling pathway called SHH, and for these patients, SHH-pathway inhibitors may offer new hope. Drugs that target an SHH-pathway protein called SMO work against other cancers in other parts of the body. However, medulloblastomas rapidly become resistant when treated with SMO inhibitors. As the recipient of the Miracles for Michael St. Baldrick's Research Grant, Dr. Sokolsky-Papkov will make SHH-targeted therapy newly effective for medulloblastoma using two innovations. She will use a new combination of two FDA-approved drugs, vismodegib and palbociclib. These inhibitors disrupt two different points in the pathway connecting SHH signaling to tumor growth, preventing resistance that can develop when either drug is administered alone. Furthermore, she has developed a method of packaging these drugs into tiny particles called nanoparticle micelles, which can deliver increased amounts of each drug into brain tumors. Dr. Sokolsky-Papkov hypothesizes that the combination of palbociclib and vismodegib, delivered for the first time in nanoparticle micelles, will advance brain tumor treatment and bring new effectiveness to medulloblastoma therapy. This grant is named for the Miracles for Michael Fund created in memory of Michael Orbany who was diagnosed with medulloblastoma when he was six years old. Even through treatment and relapse, Michael had unwavering faith and perseverance, wanting most to make others happy. This fund honors his tremendous strength to never ever give up.
Aykut Uren M.D.
Funded: 07-01-2018
through 06-30-2019
Funding Type: Research Grant
Institution Location:
Washington, DC
Institution: Georgetown University
affiliated with MedStar Georgetown University Hospital
Ewing Sarcoma (ES) is a type of cancer growing in or around bones in children and young adults. A protein called CD99 is present on all ES cells and inhibition of CD99 by different means kill ES cells. As of today none of these methods of CD99 inhibition is available as a clinical tool. Dr. Uren's team recently discovered that an FDA approved drug, clofarabine, can do the same and kill ES cell by directly binding and blocking CD99. Since clofarabine is already FDA approved, it can be tested on children with ES immediately in a Phase II clinical trial. Clofarabine is currently used in leukemia patients in the clinic due to its ability to inhibit different proteins in the cell. Since his findings suggest that there is a novel mechanism that was not known before, it is critical to establish how exactly inhibition of CD99 in ES cells lead to their death. That knowledge is the key to initiate a Phase II clinical trial with ES patients. This project will provide the missing information and accelerate design of new clinical trials based on CD99 inhibition.
Paul Weiss Ph.D.
Funded: 07-01-2018
through 06-30-2019
Funding Type: Research Grant
Institution Location:
Los Angeles, CA
Institution: University of California, Los Angeles
affiliated with Mattel Children's Hospital
Some childhood cancers do not respond to chemotherapy, surgery, or radiation. For these patients, researchers are developing a new set of treatments that use their own immune system to attack the cancer. To turn on these defenses, they need to bolster the DNA in 200 million immune cells, efficiently and safely. Unlike other strategies, these cells do not need to come from the patients, who are already weakened. Dr. Weiss has invented an engineering solution to do so and is testing it so that he can make this treatment widely available to patients and their doctors soon.
Corinne Linardic M.D., Ph.D.
Funded: 07-01-2018
through 12-31-2020
Funding Type: Research Grant
Institution Location:
Durham, NC
Institution: Duke University Medical Center
affiliated with Duke Children's Hospital & Health Center
Rhabdomyosarcoma (RMS) is a cancer with features of skeletal muscle, and the most common soft connective tissue cancer of childhood. The alveolar variant of RMS (abbreviated ARMS) is particularly hard to cure. If we could figure out which proteins in ARMS cancer cells work together to drive this cancer, we might also be able to figure out which are good drug targets. A common genetic error in ARMS is the mutant protein PAX3-FOXO1, which turns on cellular programs that cause ARMS cells to keep dividing. However, PAX3-FOXO1 is not a good drug target, and it does not work alone it physically interacts with other proteins that carry out its cancer-causing instructions. Here, Dr. Linardic and colleagues will use a sophisticated new method to identify proteins in PAX3-FOXO1s cellular neighborhood, a rapid screening technology to figure out which are most crucial to ARMS, then use models of ARMS to see which of the proteins might be the best drug targets. Importantly, this project will be carried out by three research teams with unique but complementary skills working together, united in a mission to find new therapies for this difficult-to-cure cancer.
E. Anders Kolb M.D.
Funded: 07-01-2017
through 06-30-2018
Funding Type: Research Grant
Institution Location:
Wilmington, DE
Institution: Alfred I. Dupont Hospital for Children of the Nemours Foundation
Recently the Meshinchi lab discovered that mesothelin, a cancer-specific antigen, is highly expressed in a subset of childhood AML cases, a result that both highlights the distinct genetic differences between adult and pediatric cancers and opens the door for the development of more targeted therapies. Dr. Kolb is developing novel combinations of bispecific T-cell engaging antibodies, called SMITEs (Simultaneous Multiple Interaction T-cell Engagers) that will co-target mesothelin and the AML marker CD33. These T-cell engaging protein pairs physically link cancer cells to cytotoxic T-cells resulting in more potent and selective killing than single agents alone.
Emily Bernstein Ph.D.
Funded: 07-01-2017
through 06-30-2018
Funding Type: Research Grant
Institution Location:
New York, NY
Institution: Ichan School of Medicine at Mount Sinai
affiliated with Kravis Children’s Hospital at Mount Sinai
Neurons are nerve cells that populate certain regions of the human body and are responsible for transmitting chemical signals back and forth to the brain to regulate critical bodily functions. A deadly form of pediatric cancer, known as neuroblastoma, occurs when a subset of these neurons start to proliferate uncontrollably. These cancer cells can migrate and spread throughout the body, making it very challenging to treat with currently available drugs. This highly aggressive form of neuroblastoma occurs in children who are older than 18 months. At such an early age, this disease can be quite devastating and there is an imperative need to better understand how this form of neuroblastoma develops. Recent work has identified pediatric cancer mutations in distinct specialized proteins that regulate chromatin (the complex of DNA and proteins), known as chromatin remodelers. One such protein, ATRX, was recently found to be mutated frequently in neuroblastoma tumors identified in adolescent and young adults, which have poor overall survival. Dr. Bernstein is exploring a novel therapy for neuroblastoma patients that harbor ATRX mutations thorough innovative and state-of-the-art approaches. Dr. Bernstein's team is comparing the cellular changes that occur in the presence of the drug in models of neuroblastoma.
Jessica Blackburn Ph.D.
Funded: 07-01-2017
through 08-31-2018
Funding Type: Research Grant
Institution Location:
Lexington, KY
Institution: University of Kentucky Research Foundation
affiliated with Kentucky Children's Hospital
Many cancer treatments kill both normal and cancer cells. Drugs used in standard cancer treatments have long term effects in children, such as causing developmental delays or second cancers later in life. Dr. Blackburn's team is working to find new drugs that kill cancer cells, but do not affect normal cells. By discovering characteristics that are unique to cancer and finding a drug that recognizes that specific characteristic, they will be able to selectively kill cancer cells. Their research goal is to improve cancer treatments so that children can live long, normal lives after their cancer is cured.
Monika Davare Ph.D.
Funded: 07-01-2017
through 06-30-2018
Funding Type: Research Grant
Institution Location:
Portland, OR
Institution: Oregon Health and Science University
affiliated with Doernbecher Children's Hospital
Children with cancer continue to succumb to their disease, many after receiving toxic therapies like chemotherapy and radiation. Also, surviving children face life long negative health consequences ranging from learning disabilities, to more severe effects such as a higher chance of getting another cancer in adulthood. Therefore, additional, rigorous scientific research needs to be performed to develop new and effective treatment options for these kids. Cancer growing inside the body hides in plain sight of the immune system. This is because cancer cells evolve to escape recognition by the immune cells. Therefore reawakening the immune system could be a very effective way of using a patients' own attacker cells to engulf cancer cells and get rid of the disease. Dr. Davare is working to discover and test new ways to reactivate immune cells for attacking cancer cells. For this project, she has developed an innovative method to identify synthetic molecules that will uncloak the cancer cell and make it visible to the immune system for destruction. This research strategy, in the long run, will open new doors and has the potential to not only increase survival of children with cancer, but their long term quality of life as well. This grant is named for Hannah’s Heroes, a St. Baldrick’s Hero Fund created in honor of Hannah Meeson and pays tribute to her fight by raising awareness and funding for all childhood cancers because kids like Hannah “are worth fighting for.”
Patrick Grohar M.D., Ph.D.
Funded: 07-01-2017
through 06-30-2018
Funding Type: Research Grant
Institution Location:
Grand Rapids, MI
Institution: Van Andel Research Institute
affiliated with Helen Devos Children's Hospital, Spectrum Health Hospitals
The goal of this study is to develop new therapies for Ewing sarcoma by targeting a protein called EWS-FLI1. Many people believe that the key to improving outcomes for Ewing sarcoma patients is to develop new drugs that block EWS-FLI1. In order for this to be successful, there is a need to understand exactly what happens to the Ewing sarcoma cell when EWS-FLI1 is turned off. Dr. Grohar is using the latest technology to both characterize the consequence of EWS-FLI1 silencing and identify novel compounds that turn EWS-FLI1 off.
Katherine Hyde Ph.D.
Funded: 07-01-2017
through 06-30-2019
Funding Type: Research Grant
Institution Location:
Omaha, NE
Institution: University of Nebraska
affiliated with Children's Hospital & Medical Center, Nebraska
Acute myeloid leukemia (AML) is a cancer of the immature cells in the bone marrow. One common chromosomal abnormality found in pediatric AML is the inversion of chromosome 16 (inv(16)). Current treatments for inv(16) AML are associated with significant toxicity, as well as serious long-term chronic effects. Therefore, there is a pressing need to develop new, more targeted treatments for children with inv(16) AML. Inv(16) generates a fusion gene called CBFB-MYH11. CBFB-MYH11 causes changes in gene expression, which are the first step in the development of leukemia. Because Cbfb-MYH11 is expressed in all inv(16) leukemia cells, it makes an attractive drug target. Currently, there are no CBFB-MYH11 inhibitors suitable for use in humans. However, it is possible that other proteins cooperate with CBFB-MYH11, some of which may be better drug targets. One potential co-factor is HDAC1. Dr. Hyde's team found that HDAC1 binds CBFB-MYH11 and is required for its activity. They also found that an HDAC1 inhibitor significantly blocks the growth leukemia cells in culture. In this project, Dr. Hyde is testing whether HDAC1 is an important co-factor of CBFB-MYH11 and if HDAC inhibitors effectively target Cbfb-MYH11+ leukemia cells in vivo. These results will have direct clinical implications for children with inv(16) AML.
Paul Jedlicka M.D., Ph.D.
Funded: 07-01-2017
through 06-30-2018
Funding Type: Research Grant
Institution Location:
Denver, CO
Institution: University of Colorado
affiliated with Children's Hospital Colorado
Ewing Sarcoma is an aggressive disease affecting children and young adults. Patients are treated with intensive chemotherapy. This helps some, but not all, with early disease, works poorly in those with advanced disease, and can have serious side effects. Searching for new and better therapies, Dr. Jedlicka's lab has found a new protein that works abnormally in Ewing Sarcoma and that could be a new target for treatment. Dr. Jedlicka is working to understand more about how this protein works and how best to block it, to see if it could be a useful new treatment.
Kevin Jones M.D.
Funded: 07-01-2017
through 12-31-2018
Funding Type: Research Grant
Institution Location:
Salt Lake City, UT
Institution: University of Utah
affiliated with Huntsman Cancer Institute
Synovial sarcoma is a soft-tissue cancer in adolescents and young adults. More than half of patients develop metastasis, or spread of the cancer to the lungs. Once it has metastasized, synovial sarcoma is fatal in nearly all patients. Dr. Jones' team has developed a model of synovial sarcoma and found that when the tumor spread to the lungs many white blood cells begin to infiltrate the tumors. He is studying whether these particular white blood cells from the immune system are trying to fight the tumor or are helping the tumor grow and spread to the lungs. This team is testing if the presence of these immune cells in a large panel of human synovial sarcomas are associated with the same patients developing clinical spread of disease.
Theresa Keegan Ph.D.
Funded: 07-01-2017
through 06-30-2018
Funding Type: Research Grant
Institution Location:
Sacramento, CA
Institution: University of California, Davis School of Medicine
affiliated with UC Davis Children's Hospital
Adolescent and young adult (AYA) cancer survivors have an elevated risk of medical problems that can impact the quality and length of their lives, but few studies have focused on the occurrence of late medical conditions in this population. Using data on nearly all AYA cancer survivors in California, the Rich and Weissman Family Lymphoma Survivorship Fund St. Baldrick's Research Grant is identifying how often specific late medical conditions occur and how the risk of these medical conditions vary by clinical and patient factors. The results of the study will identify subgroups of young patients at increased risk of serious medical conditions, information critical to improving survivorship care and outcomes. Jared Weissman is a Hodgkin’s lymphoma survivor thanks to a clinical trial made possible by research. This Hero Fund honors his survivorship and his grandparents, Terri and Barry Rich, by funding research for new treatment options for cures and less toxic after effects for survivors.
David Kirsch M.D., Ph.D.
Funded: 07-01-2017
through 06-30-2018
Funding Type: Research Grant
Institution Location:
Durham, NC
Institution: Duke University Medical Center
affiliated with Duke Children's Hospital & Health Center
Diffuse intrinsic pontine glioma, also referred to as brainstem glioma, is a pediatric cancer that accounts for the majority of deaths from brain tumors in children. Although radiation therapy is the standard of care for brainstem gliomas, the median survival of children with this tumor type is less than one year from diagnosis. In order to improve the treatment of these patients, Dr. Kirsch's team is using a model of brainstem glioma that can be used to evaluate the effectiveness of new therapies. Using this model, they are testing whether removing a protein called ATM, which is the target of drugs now entering clinical trials, will enhance radiation sensitivity in brainstem gliomas. They hypothesize that deleting this target, when given in combination with radiation therapy, will increase the number of tumor cells killed by radiation and will therefore improve survival in brainstem gliomas when they have a specific gene mutation commonly found in this childhood brain tumor. If successful, these studies will inform the design of future clinical trials testing this strategy in children with brainstem gliomas. This grant is named for Hannah’s Heroes, a St. Baldrick’s Hero Fund created in honor of Hannah Meeson and pays tribute to her fight by raising awareness and funding for all childhood cancers because kids like Hannah “are worth fighting for.”
Angelique Whitehurst Ph.D.
Funded: 07-01-2017
through 06-30-2019
Funding Type: Research Grant
Institution Location:
Dallas, TX
Institution: University of Texas Southwestern Medical Center at Dallas
Cancer cells are hard to defeat because they are so similar to normal cells. Most current methods that kill cancer cells impose collateral damage on normal cells that lead to immune suppression, hair loss, and gastro-intestinal damage. Dr. Whitehurst's research focuses on identifying therapies that will only kill tumor cells but leave normal cells unharmed. Here, she is focused on a tumor type that impacts adolescents: Ewing Sarcoma. She has identified a pathway, called TNFa, which is mis-wired in these cancer cells. Instead of dying when this pathway is activated, the cancer cells keep growing. Importantly, she has identified inhibitors of the pathway that can kill these tumor cells. Dr. Whitehurst is working to understand how this pathway is mis-wired in cancer cells and the consequences of its inhibition. The end goal would be the identification of chemical inhibitors that could be used in the clinic as a less toxic and more effective treatment option.
Loren Walensky M.D., Ph.D.
Funded: 07-01-2017
through 06-30-2018
Funding Type: Research Grant
Institution Location:
Boston, MA
Institution: Boston Children's Hospital
affiliated with Dana-Farber Cancer Institute, Harvard Medical School
High grade gliomas (HGG) are a vicious subtype of pediatric brain tumors that remain the leading cause of death among children with cancer. New therapeutic strategies are urgently needed to combat this scourge. By mining genomic datasets from HGGs, Dr. Walensky's team has identified a unique susceptibility profile based on retention of wild-type p53 status and dual expression of the negative regulators HDM2 and HDMX. Whereas p53 can be mutated or deleted to avoid cell cycle arrest or apoptosis, a frequent alternative mode of p53 suppression relies on overexpression of HDM2 and HDMX. Small molecules have been developed to target HDM2 specifically, but co-expression of HDMX causes resistance. Only a stapled peptide modeled after the critical p53 transactivation helix is capable of blocking both HDM2 and HDMX, a feature that has prompted its advancement to Phase I/II clinical trials in adult cancers. As the recipient of the St. Baldrick’s Research Grant with generous support from the Team Campbell Foundation, Dr. Walensky is testing a novel therapeutic strategy for pediatric HGG based on a dual-targeting stapled peptide inhibitor of HDM2/HDMX. He believes that the proof-of-concept data to emerge could provide a compelling rationale for conducting a clinical trial in these otherwise rapidly fatal pediatric brain cancers. The Team Campbell Foundation was created in memory of Campbell Hoyt who passed away from Anaplastic Ependymoma. Their mission is to improve the lives of families facing a childhood cancer diagnosis through raising awareness, funding research and providing psycho-social enrichment opportunities.
William Weiss M.D., Ph.D.
Funded: 07-01-2017
through 06-30-2018
Funding Type: Research Grant
Institution Location:
San Francisco, CA
Institution: University of California, San Francisco
affiliated with UCSF Benioff Children's Hospital
Half of neuroblastomas are high-risk neuroblastoma, with poor survival. Understanding abnormalities that drive high-risk neuroblastoma (drivers) enables development of therapies against specific drivers. Until 2015, we had identified drivers for half of high-risk neuroblastomas. Recently, most remaining high-risk neuroblastomas were shown to have high levels of TERT, a protein that helps chromosomes replicate. It is still not clear how a protein that helps chromosomes replicate could drive cancer. Perhaps TERT is needed for neuroblastoma tumors to grow, but is not driving the tumor. To distinguish these possibilities, Dr. Weiss is testing whether TERT can drive neuroblastoma in human stem-cell models. In Dr. Weiss' system, stem cells generated from normal human blood or skin cells, are differentiated to form a cell type called neural crest, from which neuroblastoma is derived. He is introducing known drivers into these cells to generate a model for neuroblastoma. Some known drivers (MYCN) lead to neuroblastoma, while others (ALK) do not. Dr. Weiss is using this model to test whether TERT is a driver, or is required for neuroblastoma in the context of other drivers (ALK). Successful completion will generate a model to evaluate whether therapy directed against TERT could help children with neuroblastoma. This grant is generously supported by the Amanda Rozman Pediatric Cancer Research Fund created in memory of Amanda Rozman and honors her courageous battle with neuroblastoma by funding promising new to improve the efficacy and number of treatments available for relapsed and refractory neuroblastoma.